Skip to main content
. 2017 Jan 10;6(2):163–166. doi: 10.3892/mco.2017.1128

Table IV.

Comparison of prognosis in stage IV gastric cancer patients.

Trial (chemotherapy regimen) OS (months) Refs.
JCOG9912 (S-1) 11.4 (22)
SPIRITS (SP) 13.0 (3)
ToGA (HXP) 13.8 (7)
Our cases (conversion surgery) 29.0

OS, overall survival; SP, S-1 + cisplatin; HXP, trastuzumab + capecitabine + cisplatin.